SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
These are morphologically polymorphic lesions composed of immunoblasts, plasma cells and small and intermediate sized lymphoid cells that efface the architecture of lymph nodes or form destructive extranodal masses. This is the most common PTLD in children and follows primary EBV infection.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010 see codes 9970/1 or 9975/1.) PTLD is a lymphoid proliferation arising in a recipient of a solid organ transplant, allogeneic bone marrow transplantation, or an umbilical cord blood transfusion.
There are two types of lymphoproliferative disorders: polymorphic and monomorphic.
Monomorphic PTLD is a PTLD that has an accompanying B-cell lymphoma, T-cell lymphoma, classical Hodgkin lymphoma, or a plasmacytoma. When there is both a PTLD and a lymphoma or plasmacytoma, the histology is coded to the lymphoma or plasmacytoma. The patient receives treatment for the lymphoma or plasmacytoma. See Rule M14 and PH1 in the Hematopoietic manual.
Polymorphic PTLD does not have an accompanying lymphoma or plasmacytoma. Polymorphic PTLD commonly involves lymph nodes, GI tract, lungs and liver. CNS involvement is rare; however in solid organ recipiants, the CNS may be the only site of involvement or may be associated with multi-organ involvement. Ceasing immunosupressing drugs commonly lead to a regression or complete absence of the PTLD..
The frequency of polymorphic Post-transplant lymphoproliferative disorder (P-PTLD) in children frequently follows primary EBV infection. Ceasing immunosuppresing drugs leads to a regression in a variable proportion of cases. Others progress and require treatment for lymphoma.
The patient must have a history of a solid organ transplant or an allogenic bone marrow transplant. The polymorphic PTLD is actually caused by the post-transplant T-cell immunosuppressant drugs. Most cases of polymorphic PTLD occur within a year of transplantation; however, they can occur anytime after the transplant.
Treatment for the polymorphic PTLD is the decrease or cessation of immunosuppressant drugs.